Clinical trials: CKD Stage 5
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in…
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Trial name
- NCT03588884
- Testing
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- OPKO Health, Inc.
Gout, CKD Stage 1-4
The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
This trial aims to investigate the impact of two target levels uric acid-lowering therapy (ULT) caused by hyperuricemia (HU) on kidney function and CKD progression [1] measured by eGFR and albuminuria (A) [2].
- Conditions
- Gout, CKD Stage 1-4, SUA Level (>8 mg/dL; 480 µmol/L)
- Trial name
- IMPULsKF (NCT03336203)
- Testing
- Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
- Where
- Ukraine
- Volunteers
- 2 people
- Sponsor
- Medical Practice Prof D. Ivanov
CKD Stage 3, CKD Stage 4
The Iron and Muscle Study
This is a multi-center randomized controlled trial that will examine the efficacy of IV iron supplementation when compared to placebo, with and without exercise training, on changes in patient exercise capacity.
- Conditions
- CKD Stage 3, CKD Stage 4, Iron-deficiency
- Trial name
- NCT04862715
- Testing
- Ferinject
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- King's College Hospital NHS Trust
Chronic Kidney Disease (CKD) Stage 5
Effect of Pre-emptive Assessment of Self-care Peritoneal Dialysis (PD) Ability on PD Choice in Patients With Stage 5 Chronic Kidney Disease
Peritoneal dialysis is an effective renal replacement therapy with higher quality of life and lower treatment cost than hemodialysis.However, the application rate of peritoneal dialysis is much lower than that of hemodialysis.
- Trial name
- NCT04967547
- Testing
- Self-care PD ability assessment form, Education
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hypercholesterolemia, CKD Stage 5
Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol, reducing in turn the risk of cardiovascular events.
- Conditions
- Hypercholesterolemia, CKD Stage 5, Chronic Kidney Disease Requiring Chronic Dialysis
- Trial name
- NCT04659525
- Testing
- Evolocumab, Ezetimibe
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Policlinico Casilino ASL RMB
CKD (Chronic Kidney Disease) Stage 5D
Impact of CKD on Children and Their Families
Based on the available literatures, previous studies have investigated the impact of CKD and dialysis on patient's health among adult and elderly population.
- Trial name
- NCT04538443
- Testing
- functional capacity, muscle strength, Quality of life of children
- Volunteers
- 100 people
- Sponsor
- Cairo University
CKD Stage 3/4
Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients
The purpose of this study is to identify genes that are responsive to paricalcitol (active vitamin D) therapy. Scientists have found that over 30 different types of cells in the body respond to vitamin D therapy, including blood…
- Trial name
- NCT02018133
- Testing
- Vitamin D 2mg daily for 2 weeks oral paricalcitol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Illinois at Chicago
CKD Stage 4
Could Ketoanalogue-supplemented Low Protein Diet Defer Dialysis in Advanced Diabetic Kidney Disease? (K-DDD)
This is a prospective single center open label randomized controlled trial aiming to assess the effectiveness and safety of a low protein diet (0.6 g/kg-day, mainly vegetarian) supplemented with ketoanalogues of essential…
- Trial name
- K-DDD (NCT03415074)
- Testing
- Protein restriction
- Where
- Romania
- Volunteers
- 120 people
- Sponsor
- Anemia Working Group Romania
CKD Stage 4
Serum Hepcidin, Haemoglobin Level and Iron Status in Chronic Kidney Disease Patients (CKD) With Anaemia
The current study is planned to assess possible relationships of serum hepcidin levels with haemoglobin levels, inflammation and iron statuses in stage 4 CKD patients.
- Trial name
- NCT04102319
- Testing
- serum hepcidin
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Assiut University
CKD Stage(III,IV,V) and Haemodialyzed Patients
Upper Endoscopy in CKD&ESRD
the study is To determine the necessity of upper gastrointestinal endoscopy in CKD(stage III---V) and haemodialyzed patients with upper GIT symptoms
- Trial name
- NCT04098120
- Volunteers
- 60 people
- Sponsor
- Assiut University
CKD (Chronic Kidney Disease) Stage 5D
NGAL and Hepcidin Levels in Hemodialysis Patients in Assiut University Hospital
To assess the pattern of NGAL and Hepicidin in relation to anemia in End Stage Renal Disease Patients on regular hemodialysis in Assiut University Hospital and study the relation between both NGAL and Hepicidin.
- Trial name
- NCT04083664
- Testing
- NGAL and Hepcidin
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Assiut University
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.
- Conditions
- End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy
- Trial name
- TRANSFORM (NCT01950819)
- Testing
- Induction therapy, Corticosteroids, EVR+rCNI
- Where
- 184 sites in United States, Argentina and 40 more
- Volunteers
- 2,037 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Providing Resources to Enhance African American Patients' Readiness to Make Decisions About Kidney Disease (PREPARED) Study
African Americans are less likely than Whites to receive kidney transplants, despite their being more than two-fold as likely as Whites to develop end stage renal disease (ESRD).
- Trial name
- PREPARED (NCT01439516)
- Testing
- Information
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Johns Hopkins University
CKD Stage 3b, CKD Stage 4
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
The aim of this study is to investigate effects of sevelamer carbonate on reducing TMAO in stage 3b-4 CKD (pre-dialysis) patients.
- Trial name
- NCT03596749
- Testing
- Sevelamer Carbonate
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fan Fan Hou
CKD (Chronic Kidney Disease) Stage 5T, Diabetes Mellitus
Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients
A single-centre, prospective, observational study to evaluate the safety and efficacy of Polyclonal Antibodies in simultaneous Pancreas Kidney Transplant recipients.
- Conditions
- CKD (Chronic Kidney Disease) Stage 5T, Diabetes Mellitus, Simultaneous Pancreas Kidney Transplantation
- Trial name
- PAISPK (NCT03470961)
- Testing
- Anti-Tlymphocyte Globulins, Anti-Thymocyte Globulins
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tianjin First Central Hospital
Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
Impact of Vitamin D Therapies on Chronic Kidney Disease
This investigation will consist of a prospective study utilizing two separate populations of patients with 25(OH)D deficiency, one population with chronic kidney disease (CKD) and one with normal renal function.
- Trial name
- NCT01222234
- Testing
- Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Kansas Medical Center
Chronic Kidney Disease (CKD), End-Stage Renal Disease (ESRD)
Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)
In the United States, African Americans are 3.6 time and Hispanics 1.5 times more likely to suffer from chronic kidney disease and need dialysis treatment for life, when compared to the non-Hispanic Whites.
- Trial name
- MADRAD (NCT01415570)
- Where
- United States
- Volunteers
- 1,050 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)
Open-label, pharmacodynamic, safety, pharmacokinetic and efficacy study of Lunacalcipol Injection.
- Conditions
- Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT), Hemodialysis (HD)
- Trial name
- 2007 (NCT01453634)
- Testing
- Lunacalcipol 180, Lunicalcipol 270
- Sponsor
- OPKO Health, Inc.
CKd Patients With Stage 3 and 4
Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD
Vitamin D deficiency is common in CKD and assciated with CV complications. Endothelial dysfucntion is common in CKD and is a harbinger of atherosclerosis.
- Trial name
- NCT02005718
- Testing
- Cholecalciferol
- Volunteers
- 36 people
- Sponsor
- St George's, University of London
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).
- Trial name
- PRIMO II (NCT00616902)
- Testing
- paricalcitol injection 4 mcg/mL
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 12 people
- Sponsor
- Abbott